Page 402 - CHHA Binder 2.3.20

4/11/2019

Glucose-lowering Potential of Injection
Diabetes Therapies

Treatment FPG ↓ A1C ↓
Exenatide (Byetta BID) targets ppd 1 - 1.5%

Liraglutide (Victoza QD) targets ppd 1 - 1.5%

Pramlintide (Symlin TID/AC) targets ppd 1 - 2%
Exenatide ER (Bydureon QW) targets ppd 1 – 2%

Dulaglutide (Trulicity QW) targets ppd 1 – 2%

Insulin Limited by 1.5-3.5%
hypoglycemia

Intensifying Treatment

Beta-cell function declines as Type 2 diabetes progresses

100
Diagnosis Beta-cell decline exceeds 50%
75
by time of diagnosis
Beta-cell IGT Insulin
function (%) 50 initiation
Postprandial
25 Hyperglycemia Type 2 Diabetes
0
12 8 4 0 4 8 12
Years from diagnosis

Lebovitz H. Diabetes Rev 1999;7:139-153.

6